Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Appyea Inc (OP:APYP)

0.0115 UNCHANGED
Streaming Delayed Price Updated: 9:30 AM EDT, Jul 2, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Appyea Inc

AppYea Chairman Bary Molchadsky Demonstrates Confidence by Converting Debt to Warrants with a Strike Price Set at a 250% Premium to Current Market Price of the Company’s Common Stock
Via ACCESSWIRE
AppYea Launches E-Commerce Store on Amazon Broadening Distribution
Via ACCESSWIRE
AppYea Enters Commercial Phase with First Deliveries of AppySleep to Customers in the U.S.
Via ACCESSWIRE
AppYea Provides Year-End Letter to Shareholders Recapping Key Achievements and Sharing Outlook for 2024
Via ACCESSWIRE
AppYea Secures US Patent for Innovative Sleep Apnea Detection Using Speech Analysis
Via ACCESSWIRE
AppYea Announces Equity Financing Transaction to Accelerate Commercial Launch
Via ACCESSWIRE
AppYea takes steps for Future Growth
(OTCPINK: APYP) 
Via News Direct
AppYea Announces Appointment of Leading Medical Device Industry Executive Adi Shemer as CEO
Via ACCESSWIRE
Leading Operations Executive Adi Shemer Joins AppYea's Advisory Board
Via ACCESSWIRE
Ron Mekler Joins AppYea's Board of Directors Audit Committee Chair
Via ACCESSWIRE
SleepX has Started Marketing its Flagship Product, DreamIT - an AI-Based Wristband to Treat the Snoring Problem Through Biofeedback
Via ACCESSWIRE
First version of the SleepX APP has been uploaded to the Google Play Store
The app is available for free download for all versions of Android starting with version 7.0. 
Via News Direct
First version of the SleepX APP has been uploaded to the Google Play Store
SleepX, a subsidiary of AppYea (OTC: APYP) a Company that is focused on the development of accurate wearable monitoring solutions to treat sleep apnea and snoring, announces that the first version of... 
Via TheNewswire.com
SleepX approved by the Helsinki Committee to conduct clinical trial with the SleepX PRO smartphone application
SleepX, a subsidiary of AppYea (OTC: APYP) focusing on the development of accurate wearable monitoring solutions to treat sleep apnea and snoring, announces it received approval from the Helsinki... 
Via TheNewswire.com
Topics Artificial Intelligence
SleepX approved by the Helsinki Committee to conduct clinical trial with the SleepX PRO smartphone application
SleepX approved by the Helsinki Committee to conduct clinical trial with the SleepX PRO smartphone application 
Via News Direct
Topics Artificial Intelligence
AppYea expands its SleepX patent commercialization portfolio with a non-diluting agreement.
SleepX signed a new commercialization agreement for two new patents. The SleepX PRO solution is designed to diagnose sleep apnea using only a smartphone, with no physical contact. 
Via News Direct
Topics Intellectual Property
AppYea expands its SleepX patent commercialization portfolio with a non-diluting agreement.
AppYea (OTC: APYP) announced that its subsidiary SleepX, which focuses on the development of accurate wearable monitoring solutions to treat sleep apnea and snoring – has signed new commercialization... 
Via TheNewswire.com
Topics Artificial Intelligence Intellectual Property
AppYea completes acquisition of SleepX, entering a $6-9 billion sleep treatments market: expects to begin marketing during 2H2022
AppYea completes acquisition of SleepX, entering a $6-9 billion sleep treatments market: expects to begin marketing during 2H2022 
Via News Direct
Vinergy Appoints Todd Violette as CEO and Director to Drive Focus on Blockchain & Bitcoin Growth Opportunities
Vancouver, British Columbia--(Newsfile Corp. - April 20, 2021) - Vinergy Capital, Inc. (CSE: VIN) (OTCQB: VNNYF) (FSE: 1V70) ("Vinergy" or the... 
Via Newsfile
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.